The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...
Panelists discuss how the chronic nature of retinal diseases requires consistent VEGF suppression through regular anti-VEGF injections, but this treatment burden leads to challenges including patient ...
Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating ...
Video content above is prompted by the following: Could you briefly provide an overview of the new treatments available for retinal vascular diseases?
Let’s look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025. Age-related macular degeneration (AMD) and geographic atrophy (GA) continue to be major ...
The ArMaDa clinical trial is currently being performed at 13 leading retinal surgery centers across the U.S. Dosing in the OCU410 ArMaDa clinical trial will be completed in early 2025 and the Company ...
Finnish researchers, Hanna Heloterä, Anna-Mari Viita, and Juha Laine, reported the results of a study in which they gained a better perspective on registry data and the changing workload in ...
Did you miss any of our print issues this year? Don’t worry, they are still available online. In an increasingly digital world, where news moves swiftly and time is crunched, digital reading has ...
A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a ...
A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery. A recent ...
The conference will be held January 13-16, 2025 in San Francisco, CA. Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development ...